Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Growth Fueled By Personal Care, Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

New launches in skin cleansing and hair care, and expansion to new geographies, drove Unilever’s personal-care division in the first fiscal quarter, the firm reports. The firm’s overall turnover reached €12.1 billion, up 11.9% versus the prior-year period.

You may also be interested in...



Axe Takes Swing At Ladies With Anarchy Body Spray

Unilever’s successful Axe brand sets its sights on the female market, targeting young women who are “friends or girlfriends of our Axe guy” with its new Anarchy For Her body spray.

What Does China's Price Manipulation Ruling On Unilever Mean For Global Pharma? (Part 2 of 2)

[Editor's note: This is part two of a two-part feature; part one covered the background of China's National Development and Reform Commission charge against consumer goods company Unilever and what multinational companies operating in China should take away from the incident. This second part looks at the larger impact of China's inflation on pharma companies.]

Unilever Diversifies Hair-Care Portfolio With $3.7 Bil. Alberto Culver Buy

Unilever says Alberto Culver's product offering will fill out its existing personal-care portfolio, strengthening its hair- and skin-care focus and growing its business in the U.S. and U.K. in particular.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC081310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel